Anurag Shrivastava, MD
Ophthalmology · Bronx
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Montefiore Medical Center · 2,809 clinicians in this group
Hospitals listed: Montefiore Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Shrivastava’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Montefiore Medical CenterBronx, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montefiore Medical Center, which runs 8 hospitalsHome of Montefiore Einstein Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 2 of 5 · 65% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.23 (1.01 to 1.45), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.96 (4.4 to 7.52) · 3,522 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 0.95 (0.64 to 1.26) · 17,685 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.679, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.584, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.283, Oct 2024 – Sep 2025
See every measure and the patient survey for Montefiore Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 1 better, 7 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.23 (1.01 to 1.45) | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.96 (4.4 to 7.52) · 3,522 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.64 to 1.26) · 17,685 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.679 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.584 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.283 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.7 (0 to 1.48) · 3,839 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 173.71 (144.1 to 203.32) · 293 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 71 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 235 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.2 · 726 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.2 · 878 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 7.5 · 1,164 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.4 · 13,803 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.1 (0 to 0.26) · 18,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.05 to 0.36) · 20,155 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.42 (0.03 to 2.82) · 1,159 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.47 (1.29 to 3.65) · 3,435 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.77 (5.48 to 16.06) · 1,120 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.47 (3.29 to 9.65) · 1,192 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.92 (0.57 to 3.28) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.8 · 1,424 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.812 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.336 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.058 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 17.8 · 722 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 2,620 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22 · 255 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18 · 840 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -6.4 · 886 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 2,180 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.1 (2.8 to 5.7) · 356 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.2 (10.5 to 16.3) · 356 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 1,427 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.9 · 170 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 22.3 · 973 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.3 to 16.2) · 803 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 627 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,904 patients answered, 11% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$25,114
Medicare paid this office $25,114 for 157 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 81 | $11,620 | $106 |
| Short return visit (20+ min) | 33 | $2,420 | $71 |
| Return visit (30+ min) | 16 | $1,638 | $96 |
| Imaging of optic nerve | 40 | $1,316 | $31 |
| Exam of visual field with extended testing | 18 | $811 | $45 |
See all 6 services
| Established patient complete exam of visual system | 81 | $11,620 | $106 |
| Short return visit (20+ min) | 33 | $2,420 | $71 |
| Return visit (30+ min) | 16 | $1,638 | $96 |
| Imaging of optic nerve | 40 | $1,316 | $31 |
| Exam of visual field with extended testing | 18 | $811 | $45 |
| Exam of the internal drainage system of eye | 13 | $266 | $19 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
157 Original Medicare patients in 2024. Average age 73 · Under 65 12% · 85 and older 10% · Women 64% · Also on Medicaid 33% · Health risk score 1.23. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 51% · Chronic kidney disease 29% · Coronary heart disease 18% · Cancer 15% · COPD 14% · Heart failure 13% · Depression 11% · Stroke 10% · Atrial fibrillation 9%.
The office billed $192,845, Medicare allowed $35,857 and paid $25,114; for 303 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 157 | 303 | 73 | 1.23 | $192,845 | $25,114 |
| 2023 | 130 | 262 | 72 | 1.28 | $142,010 | $17,878 |
| 2022 | 150 | 262 | 71 | 1.37 | $130,913 | $20,468 |
| 2021 | 134 | 271 | 70 | 1.53 | $128,145 | $19,078 |
| 2020 | 126 | 244 | 71 | 1.53 | $98,383 | $14,109 |
| 2019 | 248 | 577 | 72 | 1.50 | $200,740 | $31,583 |
| 2018 | 239 | 479 | 70 | 1.56 | $184,265 | $28,273 |
| 2017 | 268 | 524 | 71 | 1.55 | $234,872 | $32,210 |
| 2016 | 236 | 436 | 70 | 1.42 | $201,797 | $26,338 |
| 2015 | 271 | 490 | 71 | 1.63 | $131,557 | $31,087 |
| 2014 | 248 | 419 | 72 | 1.47 | $233,815 | $48,697 |
| 2013 | 310 | 689 | 70 | 1.61 | $310,097 | $71,553 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Established patient complete exam of visual system | 76 | $8,966 | $96 |
| Short return visit (20+ min) | 37 | $2,558 | $64 |
| Imaging of optic nerve | 33 | $978 | $30 |
| Exam of visual field with extended testing | 12 | $485 | $40 |
| Exam of the internal drainage system of eye | 23 | $384 | $17 |
2022: 6 services
| Established patient complete exam of visual system | 76 | $9,948 | $103 |
| Short return visit (20+ min) | 32 | $2,757 | $81 |
| New patient visit (30+ min) | 14 | $1,557 | $111 |
| Exam of visual field with extended testing | 16 | $939 | $59 |
| Imaging of optic nerve | 27 | $867 | $32 |
| Exam of the internal drainage system of eye | 12 | $292 | $24 |
2021: 6 services
| Established patient complete exam of visual system | 62 | $6,755 | $98 |
| Return visit (30+ min) | 32 | $3,416 | $100 |
| Short return visit (20+ min) | 28 | $2,232 | $77 |
| Imaging of optic nerve | 39 | $1,175 | $29 |
| Exam of visual field with extended testing | 12 | $734 | $61 |
| Exam of the internal drainage system of eye | 22 | $519 | $23 |
2020: 6 services
| Established patient complete exam of visual system | 60 | $6,180 | $90 |
| Short return visit (20+ min) | 24 | $1,525 | $59 |
| Established patient complete exam of visual system | 19 | $1,226 | $58 |
| Imaging of optic nerve | 26 | $796 | $27 |
| Exam of visual field with extended testing | 13 | $781 | $60 |
| Exam of the internal drainage system of eye | 20 | $432 | $21 |
2019: 14 services
| Established patient complete exam of visual system | 107 | $12,449 | $100 |
| Established patient complete exam of visual system | 55 | $3,939 | $64 |
| Short return visit (20+ min) | 43 | $3,084 | $57 |
| Established patient problem focused exam of visual system | 30 | $1,616 | $46 |
| Imaging of optic nerve | 48 | $1,561 | $31 |
| Established patient problem focused exam of visual system | 17 | $1,224 | $72 |
| Short return visit (20+ min) | 25 | $952 | $37 |
| Exam of visual field with extended testing | 15 | $818 | $55 |
| Exam of the internal drainage system of eye | 31 | $753 | $22 |
| New patient visit (30+ min) | 11 | $731 | $66 |
| Imaging of optic nerve | 26 | $417 | $16 |
| Exam of visual field with extended testing | 12 | $273 | $23 |
| Ultrasound scan of cornea to determine thickness | 23 | $220 | $10 |
| Ultrasound scan of cornea to determine thickness | 12 | $74 | $6 |
2018: 10 services
| Established patient complete exam of visual system | 99 | $11,103 | $93 |
| Established patient complete exam of visual system | 58 | $4,010 | $62 |
| Short return visit (20+ min) | 40 | $2,821 | $58 |
| Short return visit (20+ min) | 33 | $1,281 | $37 |
| Imaging of optic nerve | 34 | $1,159 | $33 |
| Exam of visual field with extended testing | 16 | $787 | $49 |
| Imaging of optic nerve | 26 | $404 | $15 |
| Exam of visual field with extended testing | 12 | $223 | $19 |
| Ultrasound scan of cornea to determine thickness | 17 | $217 | $13 |
| Ultrasound scan of cornea to determine thickness | 11 | $90 | $8 |
2017: 11 services
| Established patient complete exam of visual system | 103 | $12,736 | $104 |
| Established patient complete exam of visual system | 72 | $5,312 | $62 |
| Short return visit (20+ min) | 35 | $2,241 | $59 |
| Imaging of optic nerve | 34 | $1,039 | $31 |
| Short return visit (20+ min) | 23 | $1,020 | $38 |
| Established patient problem focused exam of visual system | 22 | $959 | $44 |
| Photography of the retina | 12 | $743 | $62 |
| Exam of visual field with extended testing | 17 | $339 | $19 |
| Imaging of optic nerve | 20 | $325 | $16 |
| Photography of the retina | 16 | $293 | $18 |
| Ultrasound scan of cornea to determine thickness | 20 | $239 | $12 |
2016: 14 services
| Established patient complete exam of visual system | 52 | $6,138 | $106 |
| Return visit (30+ min) | 52 | $4,580 | $80 |
| Short return visit (20+ min) | 32 | $2,049 | $59 |
| Return visit (30+ min) | 32 | $1,604 | $50 |
| Established patient complete exam of visual system | 23 | $1,469 | $64 |
| Short return visit (20+ min) | 28 | $1,188 | $40 |
| New patient visit (30+ min) | 13 | $961 | $74 |
| Photography of the retina | 13 | $961 | $74 |
| Imaging of optic nerve | 25 | $871 | $33 |
| Imaging of optic nerve | 17 | $372 | $20 |
| Exam of the internal drainage system of eye | 13 | $289 | $22 |
| Exam of the internal drainage system of eye | 13 | $186 | $14 |
| Ultrasound scan of cornea to determine thickness | 14 | $173 | $12 |
| Ultrasound scan of cornea to determine thickness | 14 | $72 | $5 |
2015: 10 services
| Established patient complete exam of visual system | 99 | $11,236 | $97 |
| Established patient complete exam of visual system | 58 | $3,804 | $62 |
| Short return visit (20+ min) | 42 | $2,781 | $53 |
| Exam of visual field with extended testing | 31 | $1,983 | $55 |
| Return visit (30+ min) | 16 | $1,650 | $97 |
| Imaging of optic nerve | 36 | $1,313 | $36 |
| Exam of visual field with extended testing | 30 | $695 | $23 |
| Short return visit (20+ min) | 16 | $596 | $37 |
| Imaging of retina | 18 | $588 | $26 |
| Imaging of optic nerve | 22 | $472 | $21 |
2014: 11 services
| Complex removal of cataract with insertion of prosthetic lens | 13 | $11,136 | $742 |
| Removal of cataract with insertion of prosthetic lens | 13 | $7,564 | $582 |
| Established patient complete exam of visual system | 68 | $5,559 | $78 |
| Established patient complete exam of visual system | 65 | $3,730 | $57 |
| Measurement of corneal curvature and depth of eye | 50 | $2,658 | $53 |
| Long return visit (40+ min) | 17 | $1,333 | $78 |
| Short return visit (20+ min) | 21 | $1,029 | $47 |
| Photography of the retina | 13 | $846 | $65 |
| Short return visit (20+ min) | 22 | $691 | $30 |
| Exam of visual field with extended testing | 20 | $490 | $25 |
| Photography of the retina | 11 | $151 | $14 |
2013: 17 services
| Removal of cataract with insertion of prosthetic lens | 15 | $10,181 | $599 |
| Complex removal of cataract with insertion of prosthetic lens | 12 | $10,149 | $725 |
| Established patient complete exam of visual system | 80 | $8,642 | $91 |
| Short return visit (20+ min) | 66 | $5,264 | $61 |
| Established patient complete exam of visual system | 67 | $4,796 | $62 |
| Return visit (30+ min) | 31 | $2,935 | $92 |
| Long return visit (40+ min) | 16 | $2,152 | $127 |
| Measurement of corneal curvature and depth of eye | 32 | $1,696 | $46 |
| Short return visit (20+ min) | 41 | $1,650 | $34 |
| Return visit (30+ min) | 28 | $1,627 | $54 |
| Photography of the retina | 26 | $1,430 | $55 |
| New patient complete exam of visual system | 12 | $1,414 | $118 |
| Exam of visual field with extended testing | 20 | $1,234 | $59 |
| Long return visit (40+ min) | 14 | $1,166 | $83 |
| Imaging of optic nerve | 26 | $912 | $35 |
| Exam of visual field with extended testing | 27 | $599 | $21 |
| Photography of the retina | 16 | $288 | $18 |
Medicaid work
$12,632 in 2024
Medicaid paid $12,632 for 225 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 201 | $11,596 |
| Short return visit (20+ min) | 12 | $916 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 12 | $120 |
| 2024 | 225 | 3 | 25 | $12,632 |
| 2023 | 195 | 2 | 27 | $12,296 |
| 2022 | 186 | 1 | 20 | $11,783 |
| 2021 | 129 | 2 | 25 | $9,961 |
| 2020 | 97 | 1 | 18 | $4,923 |
| 2019 | 309 | 2 | 33 | $20,624 |
| 2018 | 254 | 3 | 25 | $22,882 |
See the largest Medicaid services in earlier years
2023
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 169 | $9,917 |
| Short return visit (20+ min) | 26 | $2,378 |
2022
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 186 | $11,783 |
2021
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 116 | $8,798 |
| Short return visit (20+ min) | 13 | $1,162 |
2020
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 97 | $4,923 |
2019
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 255 | $17,935 |
| Short return visit (20+ min) | 54 | $2,689 |
2018
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 225 | $21,185 |
| Short return visit (20+ min) | 17 | $1,226 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 12 | $471 |
Drugs they prescribed that Part D paid
$300,663
Pharmacies billed $300,663 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,125) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
1,387 generic and 738 brand-name prescriptions · $300,663 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 159 | $100,890 | $635 |
| Lumigan | 139 | $62,885 | $452 |
| Xiidra | 37 | $29,724 | $803 |
| Combigan | 41 | $19,975 | $487 |
| Cyclosporine | 47 | $18,394 | $391 |
See all 17 drugs
| Restasis | 159 | $100,890 | $635 |
| Lumigan | 139 | $62,885 | $452 |
| Xiidra | 37 | $29,724 | $803 |
| Combigan | 41 | $19,975 | $487 |
| Cyclosporine | 47 | $18,394 | $391 |
| Rhopressa | 42 | $14,331 | $341 |
| Rocklatan | 27 | $10,696 | $396 |
| Latanoprost | 643 | $5,303 | $8 |
| Azelastine | 380 | $4,913 | $13 |
| Simbrinza | 13 | $4,818 | $371 |
| Dorzolamide-Timolol | 209 | $3,217 | $15 |
| Brimonidine | 151 | $2,413 | $16 |
| Prednisolone Acetate | 36 | $1,437 | $40 |
| Dorzolamide | 66 | $1,077 | $16 |
| Pilocarpine | 13 | $701 | $54 |
| Ketorolac Tromethamine | 21 | $413 | $20 |
| Timolol Maleate | 12 | $338 | $28 |
Year by year
| 2024 | 2,125 | 340 | 0% (0) | 35% | $300,663 |
| 2023 | 2,101 | 317 | 0% (0) | 34% | $305,172 |
| 2022 | 2,090 | 309 | 0% (0) | 35% | $294,847 |
| 2021 | 2,063 | 317 | 0% (0) | 40% | $288,226 |
| 2020 | 2,691 | 352 | 0% (0) | None | $314,744 |
| 2019 | 3,127 | 445 | 0% (0) | 41% | $338,291 |
| 2018 | 3,653 | 495 | 0% (0) | 40% | $343,682 |
| 2017 | 3,646 | 548 | 0% (0) | None | $330,151 |
| 2016 | 2,876 | 521 | 0% (0) | 43% | $223,964 |
| 2015 | 4,317 | 782 | 0% (0) | 44% | $309,497 |
| 2014 | 3,312 | 522 | None | 54% | $246,038 |
| 2013 | 3,276 | 553 | None | 58% | $221,677 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Restasis | 107 | $89,162 | $833 |
| Lumigan | 202 | $81,455 | $403 |
| Combigan | 38 | $27,050 | $712 |
| Cyclosporine | 26 | $17,844 | $686 |
| Rhopressa | 40 | $15,883 | $397 |
| Xiidra | 13 | $11,016 | $847 |
| Latanoprost | 730 | $9,617 | $13 |
| Azelastine | 307 | $7,573 | $25 |
| Rocklatan | 13 | $5,325 | $410 |
| Dorzolamide-Timolol | 183 | $4,905 | $27 |
| Travatan Z | 12 | $4,020 | $335 |
| Brimonidine | 174 | $3,592 | $21 |
| Dorzolamide | 91 | $1,979 | $22 |
| Pilocarpine | 16 | $1,230 | $77 |
| Prednisolone Acetate | 25 | $892 | $36 |
| Olopatadine | 12 | $332 | $28 |
| Ketorolac Tromethamine | 16 | $269 | $17 |
2022: 20 drugs
| Restasis | 124 | $97,328 | $785 |
| Lumigan | 175 | $64,070 | $366 |
| Combigan | 48 | $22,848 | $476 |
| Rhopressa | 45 | $13,953 | $310 |
| Cyclosporine | 19 | $11,959 | $629 |
| Alphagan P | 25 | $11,954 | $478 |
| Latanoprost | 697 | $9,889 | $14 |
| Xiidra | 12 | $7,565 | $630 |
| Dorzolamide-Timolol | 192 | $6,686 | $35 |
| Azelastine | 285 | $6,382 | $22 |
| Travoprost | 30 | $5,231 | $174 |
| Rocklatan | 13 | $4,913 | $378 |
| Simbrinza | 12 | $4,551 | $379 |
| Brimonidine | 151 | $2,707 | $18 |
| Dorzolamide | 71 | $2,021 | $28 |
| Prednisolone Acetate | 34 | $1,696 | $50 |
| Pilocarpine | 19 | $1,283 | $68 |
| Tobramycin-Dexamethasone | 11 | $764 | $69 |
| Olopatadine | 25 | $574 | $23 |
| Timolol Maleate | 25 | $289 | $12 |
2021: 17 drugs
| Restasis | 137 | $100,916 | $737 |
| Lumigan | 185 | $65,221 | $353 |
| Combigan | 86 | $31,215 | $363 |
| Rhopressa | 49 | $16,758 | $342 |
| Xiidra | 15 | $10,313 | $688 |
| Latanoprost | 685 | $8,929 | $13 |
| Alphagan P | 26 | $8,053 | $310 |
| Dorzolamide-Timolol | 177 | $6,958 | $39 |
| Travoprost | 26 | $4,890 | $188 |
| Azelastine | 242 | $4,522 | $19 |
| Brimonidine | 175 | $2,999 | $17 |
| Tobradex | 11 | $2,698 | $245 |
| Prednisolone Acetate | 42 | $2,376 | $57 |
| Dorzolamide | 88 | $2,047 | $23 |
| Pilocarpine | 19 | $1,294 | $68 |
| Olopatadine | 14 | $397 | $28 |
| Timolol Maleate | 11 | $148 | $13 |
2020: 22 drugs
| Restasis | 132 | $83,412 | $632 |
| Lumigan | 240 | $76,194 | $317 |
| Combigan | 134 | $41,681 | $311 |
| Azopt | 18 | $11,067 | $615 |
| Latanoprost | 941 | $10,678 | $11 |
| Rhopressa | 37 | $10,170 | $275 |
| Pazeo | 45 | $9,301 | $207 |
| Travatan Z | 28 | $7,833 | $280 |
| Dorzolamide-Timolol | 218 | $7,314 | $34 |
| Simbrinza | 25 | $7,116 | $285 |
| Alphagan P | 26 | $6,914 | $266 |
| Rocklatan | 20 | $5,568 | $278 |
| Travoprost | 32 | $5,321 | $166 |
| Brimonidine | 205 | $4,828 | $24 |
| Azelastine | 213 | $3,798 | $18 |
| Prednisolone Acetate | 47 | $2,875 | $61 |
| Dorzolamide | 131 | $2,855 | $22 |
| Durezol | 12 | $2,490 | $208 |
| Olopatadine | 43 | $2,306 | $54 |
| Ketorolac Tromethamine | 13 | $297 | $23 |
| Bacitracin-Polymyxin | 21 | $287 | $14 |
| Timolol Maleate | 25 | $233 | $9 |
2019: 22 drugs
| Lumigan | 266 | $72,328 | $272 |
| Restasis | 115 | $68,094 | $592 |
| Combigan | 177 | $49,841 | $282 |
| Travatan Z | 97 | $22,017 | $227 |
| Rhopressa | 57 | $14,919 | $262 |
| Alphagan P | 51 | $13,798 | $271 |
| Azopt | 28 | $13,514 | $483 |
| Latanoprost | 1,096 | $12,954 | $12 |
| Dorzolamide-Timolol | 281 | $8,809 | $31 |
| Methazolamide | 17 | $8,665 | $510 |
| Brimonidine | 259 | $8,146 | $31 |
| Pazeo | 41 | $7,939 | $194 |
| Azelastine | 229 | $5,162 | $23 |
| Simbrinza | 16 | $4,392 | $275 |
| Olopatadine | 31 | $3,688 | $119 |
| Tobradex | 12 | $2,889 | $241 |
| Dorzolamide | 118 | $2,667 | $23 |
| Prednisolone Acetate | 56 | $2,649 | $47 |
| Durezol | 13 | $2,538 | $195 |
| Pilocarpine | 17 | $1,938 | $114 |
| Timolol Maleate | 56 | $618 | $11 |
| Ketorolac Tromethamine | 15 | $435 | $29 |
2018: 22 drugs
| Lumigan | 275 | $74,103 | $269 |
| Restasis | 135 | $71,602 | $530 |
| Combigan | 225 | $54,352 | $242 |
| Alphagan P | 78 | $23,586 | $302 |
| Travatan Z | 101 | $21,457 | $212 |
| Latanoprost | 1,317 | $14,265 | $11 |
| Brimonidine | 379 | $12,336 | $33 |
| Restasis Multidose | 17 | $9,401 | $553 |
| Azopt | 31 | $9,289 | $300 |
| Dorzolamide-Timolol | 311 | $6,877 | $22 |
| Olopatadine | 66 | $5,769 | $87 |
| Prednisolone Acetate | 97 | $5,534 | $57 |
| Azelastine | 201 | $5,188 | $26 |
| Simbrinza | 22 | $5,103 | $232 |
| Pazeo | 26 | $4,655 | $179 |
| Dorzolamide | 153 | $3,122 | $20 |
| Methazolamide | 13 | $2,943 | $226 |
| Pilocarpine | 35 | $2,853 | $82 |
| Durezol | 15 | $2,592 | $173 |
| Acetazolamide | 14 | $1,974 | $141 |
| Timolol Maleate | 67 | $1,659 | $25 |
| Ketorolac Tromethamine | 29 | $969 | $33 |
2017: 20 drugs
| Restasis | 165 | $80,221 | $486 |
| Lumigan | 289 | $67,236 | $233 |
| Combigan | 191 | $38,514 | $202 |
| Alphagan P | 131 | $31,474 | $240 |
| Travatan Z | 125 | $25,159 | $201 |
| Latanoprost | 1,240 | $12,976 | $10 |
| Azopt | 48 | $12,667 | $264 |
| Brimonidine | 340 | $9,684 | $28 |
| Azelastine | 205 | $8,054 | $39 |
| Dorzolamide-Timolol | 373 | $7,691 | $21 |
| Prednisolone Acetate | 90 | $5,402 | $60 |
| Pataday | 24 | $4,504 | $188 |
| Olopatadine | 34 | $3,353 | $99 |
| Simbrinza | 16 | $2,964 | $185 |
| Acetazolamide | 20 | $2,911 | $146 |
| Pilocarpine | 39 | $2,876 | $74 |
| Dorzolamide | 127 | $2,299 | $18 |
| Timolol Maleate | 70 | $1,526 | $22 |
| Ketorolac Tromethamine | 40 | $1,335 | $33 |
| Atropine Sulfate | 12 | $428 | $36 |
2016: 18 drugs
| Lumigan | 259 | $49,679 | $192 |
| Restasis | 92 | $40,205 | $437 |
| Alphagan P | 121 | $23,755 | $196 |
| Combigan | 151 | $22,763 | $151 |
| Prednisolone Acetate | 199 | $13,732 | $69 |
| Travatan Z | 64 | $13,083 | $204 |
| Azopt | 35 | $11,116 | $318 |
| Pataday | 66 | $10,972 | $166 |
| Latanoprost | 962 | $10,491 | $11 |
| Azelastine | 152 | $6,787 | $45 |
| Dorzolamide-Timolol | 295 | $5,625 | $19 |
| Brimonidine | 197 | $4,705 | $24 |
| Simbrinza | 13 | $2,211 | $170 |
| Olopatadine | 13 | $1,346 | $104 |
| Dorzolamide | 67 | $1,237 | $18 |
| Ketorolac Tromethamine | 56 | $1,161 | $21 |
| Timolol Maleate | 47 | $368 | $8 |
| Ofloxacin | 17 | $269 | $16 |
2015: 22 drugs
| Lumigan | 309 | $55,140 | $178 |
| Prednisolone Acetate | 602 | $52,180 | $87 |
| Restasis | 85 | $33,129 | $390 |
| Combigan | 187 | $25,056 | $134 |
| Alphagan P | 161 | $23,659 | $147 |
| Patanol | 89 | $23,003 | $258 |
| Travatan Z | 108 | $18,857 | $175 |
| Pataday | 94 | $15,044 | $160 |
| Latanoprost | 917 | $11,591 | $13 |
| Ketorolac Tromethamine | 551 | $9,075 | $16 |
| Azopt | 39 | $8,615 | $221 |
| Azelastine | 129 | $6,744 | $52 |
| Ofloxacin | 368 | $6,331 | $17 |
| Dorzolamide-Timolol | 262 | $6,071 | $23 |
| Brimonidine | 164 | $4,332 | $26 |
| Pilocarpine | 35 | $3,271 | $93 |
| Methazolamide | 14 | $2,341 | $167 |
| Dorzolamide | 68 | $1,471 | $22 |
| Bacitracin | 13 | $850 | $65 |
| Timolol Maleate | 70 | $464 | $7 |
| Neomycin-Polymyxin-Dexameth | 18 | $332 | $18 |
| Cromolyn | 11 | $78 | $7 |
2014: 21 drugs
| Lumigan | 486 | $65,121 | $134 |
| Combigan | 218 | $25,234 | $116 |
| Restasis | 74 | $22,788 | $308 |
| Travatan Z | 138 | $19,297 | $140 |
| Alphagan P | 157 | $19,002 | $121 |
| Prednisolone Acetate | 269 | $18,274 | $68 |
| Latanoprost | 894 | $15,432 | $17 |
| Patanol | 63 | $10,625 | $169 |
| Dorzolamide-Timolol | 297 | $9,865 | $33 |
| Azopt | 60 | $9,311 | $155 |
| Pataday | 64 | $9,227 | $144 |
| Azelastine | 103 | $6,363 | $62 |
| Brimonidine | 138 | $4,170 | $30 |
| Methazolamide | 16 | $2,591 | $162 |
| Dorzolamide | 64 | $1,628 | $25 |
| Acetazolamide | 11 | $955 | $87 |
| Timolol Maleate | 104 | $877 | $8 |
| Pilocarpine | 11 | $830 | $75 |
| Epinastine | 12 | $747 | $62 |
| Flurbiprofen | 68 | $475 | $7 |
| Ketorolac Tromethamine | 14 | $424 | $30 |
2013: 21 drugs
| Lumigan | 526 | $61,379 | $117 |
| Restasis | 105 | $27,921 | $266 |
| Combigan | 208 | $21,488 | $103 |
| Travatan Z | 152 | $18,680 | $123 |
| Alphagan P | 143 | $15,775 | $110 |
| Latanoprost | 722 | $15,563 | $22 |
| Dorzolamide-Timolol | 244 | $9,334 | $38 |
| Pataday | 66 | $8,604 | $130 |
| Prednisolone Acetate | 384 | $8,164 | $21 |
| Azopt | 58 | $7,736 | $133 |
| Azelastine | 98 | $7,226 | $74 |
| Ketorolac Tromethamine | 145 | $3,496 | $24 |
| Brimonidine | 68 | $2,522 | $37 |
| Epinastine | 31 | $2,491 | $80 |
| Dorzolamide | 35 | $1,069 | $31 |
| Timolol Maleate | 80 | $922 | $12 |
| Ofloxacin | 92 | $829 | $9 |
| Bacitracin | 14 | $801 | $57 |
| Pilocarpine | 12 | $734 | $61 |
| Cromolyn | 19 | $406 | $21 |
| Flurbiprofen | 16 | $123 | $8 |
Money from drug and device companies
$305 in 2025
| 2025 | 1 | 3 | None | $305 |
| 2024 | 1 | 1 | None | $125 |
| 2023 | 1 | 1 | None | $87 |
| 2022 | 2 | 2 | None | $219 |
| 2021 | 3 | 4 | $325 | $511 |
| 2020 | 2 | 3 | $250 | $344 |
| 2019 | 6 | 38 | $12,210 | $22,591 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Tryptyr | $305 | 3 payments
|
See all 3 published payments
| Alcon Vision | Meals · 2025-10-18 | Clareon | $75 |
| Alcon Vision | Meals · 2025-10-14 | Tryptyr | $125 |
| Alcon Vision | Meals · 2025-07-16 | Clareon Panoptix Pro | $105 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $125
| Alcon Vision | Rocklatan | $125 | 1 payment
|
2023: $87
| Alcon Vision | Rocklatan | $87 | 1 payment
|
2022: $219
| Abbvie | Durysta | $123 | 1 payment
|
| Alcon Vision | Rhopressa | $95 | 1 payment
|
2021: $511
| Allergan | Durysta | $328 | 2 payments
|
| Aerie Pharmaceuticals | Rhopressa | $162 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $20 | 1 payment
|
2020: $344
| Allergan | Durysta | $270 | 2 payments
|
| Aerie Pharmaceuticals | Rhopressa | $74 | 1 payment
|
2019: $22,591
| Allergan | Lumigan | $19,885 | 25 payments
|
| Alcon Vision | Ngenuity | $2,192 | 5 payments
|
| Aerie Pharmaceuticals | Rhopressa | $208 | 2 payments
|
| Sight Sciences | Omni | $128 | 3 payments
|
| Johnson & Johnson Surgical Vision | Tecnis Multifocal Family of 1-Piece Iols | $99 | 2 payments
|
| Ivantis | Hydrus | $79 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Allergan, Inc. · An Extension Trial To Evaluate the Long-Term Safety and Efficacy of Bimatoprost Sr in Patients With Open Angle Glaucoma Or Ocular Hypertension · 2020 | Their institution | $35,087 |
| Allergan, Inc. · An Extension Trial To Evaluate the Long-Term Safety and Efficacy of Bimatoprost Sr in Patients With Open Angle Glaucoma Or Ocular Hypertension · 2021 | Their institution | $15,755 |
| ABBVIE INC. · Long-Term Safety and Efficacy Extension Trial of Bimatoprost Sr · 2022 | Their institution | $8,654 |
| Allergan, Inc. · The Efficacy and Safety of Bimatoprost Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension · 2020 | Their institution | $7,571 |
| Allergan, Inc. · An Extension Trial To Evaluate the Long-Term Safety and Efficacy of Bimatoprost Sr in Patients With Open Angle Glaucoma Or Ocular Hypertension · 2022 | Their institution | $4,367 |
| ABBVIE INC. · Long-Term Safety and Efficacy Extension Trial of Bimatoprost Sr · 2023 | Their institution | $3,275 |
| Allergan Inc. · The Efficacy and Safety of Bimatoprost Sr in Patients With Open-Angle Glaucoma Or Ocular Hypertension · 2019 | Their institution | $2,980 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1760518823
- Licence
- NY 00246048, NY 249681
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0009X (207WX0009X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 725 E 9th St, Apt. 2f, New York, NY, 10009
- NPI first listed
- 2007-02-25
- NPI last updated
- 2018-05-04
This is when the NPI record was last certified, not a medical board exam.